Skip to main content

Table 3 Clinical outcomes

From: The impact of vildagliptin on the daily glucose profile and coronary plaque stability in impaired glucose tolerance patients with coronary artery disease: VOGUE—A multicenter randomized controlled trial

Variables Vildagliptin group (n = 10) Control group (n = 10) p Value
Cardiac death, % 0 0  
Myocardial infarction, % 0 0  
Cerebral infarction, % 0 0  
Target lesion revascularization, % 0 10 1.000
Target vessel revascularization, % 0 20 0.473